Stay updated on Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The NIH transition announcement banner was removed from the top of the page. The underlying page continues to show a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-11-08T05:39:37.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page remains a 403 Forbidden error page.
    Difference
    0.2%
    Check dated 2026-11-01T02:39:44.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A banner announces an NIH-wide transition from using “Artificial Intelligence” to “Super Intelligence” and points visitors to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T02:49:48.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 while the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T02:39:59.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T03:30:23.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the usual study content. This blocks access to the study details and locations that were previously visible.
    Difference
    17%
    Check dated 2026-09-20T01:43:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Early NK/T-cell Lymphoma Clinical Trial page.